Clinical trial · Interventional
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
An Open Label Phase II Study of Oral Treatment With Sunitinib (SUTENT) in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen
NCT00748358CI-TRIAL-00012162PROSUTcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are still responders after 6 cycles will be treated until disease progression, pain progression, unacceptable toxicity or death due to any cause. Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability. Follow-up for up to 1 year from the last dose of sunitinib.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Disease-Free Survival | — | UNRESOLVED | — |
| Neoplasms, Hormone-Dependent | Neoplasm | ONTOLOGY_EXACT | 0.85 |
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
| Survival Rate | — | UNRESOLVED | — |
| Tumor Markers, Biological | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sunitinib | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- drug
- description
- drug
- interventionNames
- Drug: sunitinib
Primary outcomes (1)
- measure
- progression-free survival (PFS) defined as the time from start of study treatment to first documentation of objective progressive disease, pain progression or to death on-study due to any cause.
- timeFrame
- 18 months
Secondary outcomes (1)
- measure
- Incidence and intensity of Adverse Events (NCI CTCAE version 3.0).
- timeFrame
- 9 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed and dated IRB/EC-approved informed consent * Age 18 years or older * Histologically confirmed prostate adenocarcinoma * Metastatic HRPC * Received prior castration by orchidectomy and/or LH-RH agonist with or without antiandrogen, antiandrogen withdrawal, monotherapy with estramustine, or other hormonal agents. * Tumor disease must be progressive after a first line using docetaxel based chemotherapy, eventually in association with estramustine. Docetaxel based regimen may have been interrupted and restarted. Patient must have either measurable (RECIST criteria) or non-measurable (bone) disease and/or clinical progression (bone pain) and/or biological progression (PSA Working Group criteria). * Discontinuation from previous chemotherapy and/or radiation therapy at least 4 weeks prior to treatment initiation * Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) scale * Patient of child bearing potential must use effective contraception. Female partners of treated patients with child bearing potential must use oral contraceptives or intra uterine device (IUD) * Life expectancy of at least 3 months * Resolution of all acute toxic effects of any prior local treatment to NCI CTCAE grade 1 * Patients must have adequate organ functions defined * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures * Patient covered by the National Health System Exclusion Criteria: * Prior treatment with sunitinib or other antiangiogenic agent * More than 1 line of chemotherapy * External beam radiotherapy for ≥ 50% of bone marrow * Uncontrolled hypertension (systolic blood pressure \> 150 mm Hg or diastolic blood pressure \> 90 mm Hg despite optimal medical management) * Any of the following within 12 months prior to treatment initiation: severe/unstable angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive heart failure, thrombotic or embolic events such as cerebrovascular accident including transient ischemic attack * Ongoing cardiac dysrhythmias of grade 2, atrial fibrillation of any grade * Treatment with anticonvulsant agents and treatment with therapeutic doses of coumarin-derivative anticoagulants such as warfarin currently or within 2 weeks prior to first day of Sunitinib administration. Low dose of warfarin for deep vein thrombosis prophylaxis is permitted (up to 2 mg/day) and low molecular weight heparin is allowed * Any medical condition that might interfere with oral medication absorption * Known or suspected brain metastasis, or carcinomatous meningitis, or spinal cord compression * Diagnosis of any second malignancy within the last 3 years, with the exception of treated basal cell or squamous cell carcinoma and pT1/a bladder cancer with no evidence of recurrent disease for 12 months * Any acute or chronic medical or psychiatric disorder incompatible with the study * Known human immunodeficiency virus or acquired immunodeficiency syndrome-related illness * Treatment with others investigational drugs or participation in another clinical trial within the past 4 weeks, or concomitantly with this trial
References
Publications (0)
Data not yet available
No reference posted for this study.